Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE BioLight Life Sciences Investments Ltd
TEL AVIV, Israel, February 27, 2014 /PRNewswire/ --
BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Suzana Nahum-Zilberberg, chief executive officer, will present at the 26th Annual ROTH Conference on Monday, March 10, 2014 at 9:30 a.m. Pacific time. Ms. Nahum-Zilberberg will provide an overview of BioLight's business and growth strategy. The presentation will be webcast live and a link to the audio and slides will be posted in the Investor Relations section of BioLight website http://www.bio-light.co.il/202306/Overview. A replay will be available on the company's website for 365 days.
The conference is being held at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. from March 9 through March 12.
BioLight Life Sciences Investments (OTC: BLGTY, TASE: BOLT), invests in, manages and commercializes biomedical innovations grouped into "clusters" around defined medical conditions. The two current clusters are in ophthalmology via 100% ownership of XLVision Sciences, and in cancer diagnostics via a 29% controlling ownership of Micromedic (TASE: MCTC). XLVision technologies include IOPtimate™, a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D™, a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designated for colorectal, cervical, breast, bladder, lung and other cancers.
For more information please visit the Company's website at http://www.bio-light.co.il
©2012 PR Newswire. All Rights Reserved.